I don't really see a problem with the FDA reg in the bolded and underlined segment below. (1) Ecigs aren't intended for the diagnosis or treatment of a disease and (2) they aren't intended to affect the structure or function of the body in any way that is different from the effects of nicotine that were commonly and legally claimed in the marketing of cigarettes and smokeless tobacco products prior to March 21, 2000. So, given that initial statement of classification, ecigs don't meet the parameters for classification as a drug device, IMO.
Other than that, the only issue I see is that they just need to be considered as tobacco products and not pharmaceutical products, based on the statement below. This may be a step in a process that the FDA is using to incrementally build a case for moving them into the pharmaceutical realm. It's all a little too strange at this point. What is their ultimate goal?
If ecigs are sold with the statement that they may cure or mitigate the symptoms of a disease, they could be switched over from tobacco products to medical devices. If they are advertised to heal the lungs or some other part of the body, for instance, or are sold as a health aid, then they could be reclassified as drug devices.
Am I reading the clause correctly?
From the FDA link in the original post.
Other than that, the only issue I see is that they just need to be considered as tobacco products and not pharmaceutical products, based on the statement below. This may be a step in a process that the FDA is using to incrementally build a case for moving them into the pharmaceutical realm. It's all a little too strange at this point. What is their ultimate goal?
If ecigs are sold with the statement that they may cure or mitigate the symptoms of a disease, they could be switched over from tobacco products to medical devices. If they are advertised to heal the lungs or some other part of the body, for instance, or are sold as a health aid, then they could be reclassified as drug devices.
Am I reading the clause correctly?
From the FDA link in the original post.
Conceptually, the proposed rule follows the disease prong and the structure/function
prong (with certain enumerated limitations) of the statutory definitions of “drug” and “device”
(section 201(g) and (h) of the FD&C Act). Under the proposed rule, a product made or derived
from tobacco and intended for human consumption would be regulated as a drug, device, or
combination product in two circumstances: (1) If the product is intended for use in the diagnosis
of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease; or
(2) if the product is intended to affect the structure or any function of the body in any way that is
different from effects of nicotine that were commonly and legally claimed in the marketing of
cigarettes and smokeless tobacco products prior to March 21, 2000. The proposed rule also
attempts to clarify remaining circumstances where a product would be or could be regulated as a
tobacco product.
In addition, FDA is proposing to amend its existing intended use regulations for drugs
and devices by inserting in §§ 201.128 and 801.4 a reference to the proposed rule to clarify the
interplay between these regulations and this proposed rule, and to conform §§ 201.128 and 801.4
to reflect how the Agency currently applies them to drugs and devices.
Last edited: